Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)
Scope of the Report
The report titled “Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)” provides an in-depth analysis of the global AAT Replacement Therapy market with detailed analysis of market sizing, growth and market share. The report provides market size by value and volume along with the supply trend prevailing in the market.
The report provides detail market analysis of the major products available in the market for treating AAT deficiency. The four major products included are, Prolastin, Glassia, Zemaira, and Aralast. Among which, Prolastin had the monopoly in the market for over 25 years, Asit was the first AAT Replacement Therapy available in the market for the treatement.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global AAT Replacement Therapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global AAT Replacement Therapy market is stiff and dominated by the big players like Grifols. Further, key players of the AAT Replacement Therapy market, Kamada, Shire and CSL Behring are also profiled with their financial information and respective business strategies.
CSL Behring LLC
Alpha 1 antitrypsin is a type of plasma protein inside our body, it is called protease inhibitor. AAT is made in the liver and its function is to protect lungs and liver. Deficiency of AAT protein is caused by genetic defect. Adults with severe AAT deficiency develop emphysema. Smoking can increase the risk of emphysema. The market to replace AAT deficiency by replacement therapy has grown with in past 5-10 years.
The global AAT Replacement therapy market has increased at a significant CAGR during the span of 4 years i.e. 2012-2015 and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market for AAT replacement therapy has increased significantly in these years because the people as well as doctors have become more aware of the disease. Earlier, patients suffering from AAT deficiency were treated like asthma patients or other COPD patients. But, now, doctors have access to better diagnostics tests that can detect disease at the early stage.
Improvement in the method of treatment is the major driver for the growth of the market, a number of technologies and diagnostics have been innovated to treat and diagnose the same. Thus, the increased awareness along with improved treatment signifies the upsurge in the AAT Replacement Therapy market. Also, the number the of prescriptions for AAT Replacement therapy have been reported to increase at an increasing rate, driving the market in the positive direction. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as: the cost of the treatment is high for people, limited plasma fraction capacity and side-effects of alpha1 proteinase inhibitor.